S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
Log in
NASDAQ:RCKT

Rocket Pharmaceuticals Competitors

$54.33
+2.47 (+4.76 %)
(As of 02/26/2021 02:16 PM ET)
Add
Compare
Today's Range
$50.10
Now: $54.33
$55.06
50-Day Range
$51.85
MA: $57.11
$65.91
52-Week Range
$9.01
Now: $54.33
$67.48
Volume31,724 shs
Average Volume473,911 shs
Market Capitalization$3.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Competitors

Rocket Pharmaceuticals (NASDAQ:RCKT) Vs. GRFS, BHC, RDY, MRTX, BBIO, and JAZZ

Should you be buying RCKT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Rocket Pharmaceuticals, including Grifols (GRFS), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), and Jazz Pharmaceuticals (JAZZ).

Rocket Pharmaceuticals (NASDAQ:RCKT) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Grifols, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Grifols05302.38

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Grifols.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Grifols12.79%10.65%4.79%

Insider and Institutional Ownership

15.2% of Grifols shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Grifols' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
Grifols$5.71 billion1.92$700.16 million$1.1713.63

Grifols has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Summary

Grifols beats Rocket Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Bausch Health Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Bausch Health Companies05702.58

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Bausch Health Companies has a consensus price target of $30.5833, indicating a potential downside of 3.37%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Bausch Health Companies.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Bausch Health Companies-23.92%173.20%4.21%

Insider and Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
Bausch Health Companies$8.60 billion1.31$-1,788,000,000.00$4.437.18

Rocket Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Dr. Reddy's Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Dr. Reddy's Laboratories00403.00

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Dr. Reddy's Laboratories has a consensus price target of $70.00, indicating a potential upside of 16.01%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Rocket Pharmaceuticals.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Dr. Reddy's Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
Dr. Reddy's Laboratories$2.32 billion4.31$259 million$2.7921.61

Dr. Reddy's Laboratories has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Dr. Reddy's Laboratories beats Rocket Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Mirati Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Mirati Therapeutics151002.56

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Mirati Therapeutics has a consensus price target of $219.0714, indicating a potential upside of 9.55%. Given Mirati Therapeutics' higher possible upside, analysts clearly believe Mirati Therapeutics is more favorable than Rocket Pharmaceuticals.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Mirati TherapeuticsN/A-60.01%-54.21%

Insider and Institutional Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Mirati Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
Mirati Therapeutics$3.34 million3,012.95$-213,260,000.00($5.69)-35.17

Rocket Pharmaceuticals has higher earnings, but lower revenue than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Mirati Therapeutics on 8 of the 12 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and BridgeBio Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
BridgeBio Pharma01802.89

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. BridgeBio Pharma has a consensus price target of $61.2222, indicating a potential downside of 11.39%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than BridgeBio Pharma.

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
BridgeBio PharmaN/A-109.88%-48.54%

Insider and Institutional Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and BridgeBio Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
BridgeBio Pharma$40.56 million257.78$-260,590,000.00($2.48)-28.33

Rocket Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats BridgeBio Pharma on 9 of the 12 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Profitability

This table compares Rocket Pharmaceuticals and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Jazz Pharmaceuticals7.86%20.16%10.85%

Volatility and Risk

Rocket Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Jazz Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-34.51
Jazz Pharmaceuticals$2.16 billion4.39$523.37 million$14.6011.68

Jazz Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rocket Pharmaceuticals and Jazz Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011202.92
Jazz Pharmaceuticals111602.83

Rocket Pharmaceuticals currently has a consensus price target of $57.8889, indicating a potential upside of 6.83%. Jazz Pharmaceuticals has a consensus price target of $181.00, indicating a potential upside of 6.14%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Rocket Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Ad All Marijuana Stocks
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.

Rocket Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Grifols logo
GRFS
Grifols
1.2$15.95+2.6%$11.26 billion$5.71 billion14.24Gap Up
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$31.82+1.7%$11.11 billion$8.60 billion-5.84Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.28+0.5%$10.04 billion$2.32 billion49.82
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.2$200.14+2.3%$9.83 billion$3.34 million-25.99Earnings Announcement
News Coverage
Gap Down
BBIO
BridgeBio Pharma
1.6$70.27+7.3%$9.69 billion$40.56 million-20.61Earnings Announcement
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$170.51+0.1%$9.51 billion$2.16 billion53.79Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$141.19+3.5%$9.12 billion$103.71 million-32.16Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.2$150.36+2.0%$8.56 billion$12.98 million-49.62Upcoming Earnings
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$81.95+0.3%$8.53 billion$87.99 million-97.56
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$154.03+3.0%$8.47 billion$14.98 million-18.76News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$49.00+3.4%$7.52 billion$339.08 million-28.49Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$168.25+0.3%$7.50 billion$1.45 billion15.92Earnings Announcement
Analyst Report
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$52.31+2.1%$7.47 billion$1.12 billion108.98Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
SDGR
Schrödinger
1.3$103.38+1.1%$7.26 billion$85.54 million0.00Upcoming Earnings
Insider Selling
News Coverage
Gap Up
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$86.88+1.9%$6.73 billion$380.83 million-11.11Upcoming Earnings
Analyst Report
News Coverage
AVIR
Atea Pharmaceuticals
1.7$79.45+2.3%$6.72 billionN/A0.00
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$215.09+0.1%$6.67 billion$311.33 million-125.05Analyst Revision
Allakos logo
ALLK
Allakos
1.2$123.36+4.1%$6.21 billionN/A-45.02Upcoming Earnings
Analyst Report
Analyst Revision
Gap Down
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.53+2.3%$5.72 billion$150,000.00-21.00Upcoming Earnings
TPTX
Turning Point Therapeutics
1.9$116.62+0.2%$5.63 billionN/A-33.23Upcoming Earnings
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$98.55+2.5%$5.57 billion$66.51 million18.18Analyst Report
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$82.85+2.8%$5.57 billion$1.00 billion-12.55Analyst Upgrade
Gap Up
Perrigo logo
PRGO
Perrigo
2.6$39.20+4.0%$5.57 billion$4.84 billion-653.22Upcoming Earnings
Dividend Increase
Unusual Options Activity
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$31.76+1.3%$5.43 billionN/A0.00Upcoming Earnings
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$96.16+1.0%$5.18 billion$1.11 billion30.92Analyst Upgrade
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.4$85.80+3.1%$4.98 billionN/A-6.99Upcoming Earnings
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.50+1.3%$4.62 billion$806.43 million-11.40Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$69.01+4.6%$4.56 billion$36.13 million-103.00Upcoming Earnings
FibroGen logo
FGEN
FibroGen
1.4$50.27+0.8%$4.54 billion$256.58 million-19.26Upcoming Earnings
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$82.24+1.5%$4.34 billion$6.87 million-7.95Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.79+0.0%$4.34 billion$204.89 million-37.24Upcoming Earnings
News Coverage
IMAB
I-Mab
0.9$59.61+1.9%$4.21 billion$4.31 million-2.06Analyst Report
Gap Down
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$122.41+0.6%$4.20 billion$26.52 million-10.79Upcoming Earnings
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$23.45+4.3%$4.03 billion$114.62 million-9.46Earnings Announcement
News Coverage
Insmed logo
INSM
Insmed
1.2$36.61+1.5%$3.79 billion$136.47 million-14.08Earnings Announcement
News Coverage
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$56.82+2.9%$3.77 billion$306.98 million-8.13Earnings Announcement
Analyst Report
News Coverage
LEGN
Legend Biotech
1.2$26.95+2.0%$3.63 billion$64.39 million0.00
ARVN
Arvinas
2.0$77.04+4.0%$3.58 billion$42.98 million-30.09
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$48.32+4.1%$3.49 billion$117.91 million-9.80Earnings Announcement
Analyst Downgrade
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.8$48.54+7.2%$3.41 billionN/A-6.54Earnings Announcement
Analyst Report
News Coverage
Gap Down
MorphoSys logo
MOR
MorphoSys
0.4$25.06+2.1%$3.37 billion$80.43 million119.34News Coverage
KRTX
Karuna Therapeutics
1.6$125.51+3.7%$3.24 billionN/A-62.44Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$74.77+0.4%$3.23 billion$421.03 million26.33Earnings Announcement
Analyst Report
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.13+1.7%$3.11 billion$182.24 million-10.55Upcoming Earnings
Alkermes logo
ALKS
Alkermes
1.2$18.87+3.0%$3.10 billion$1.17 billion-41.02
ALXO
ALX Oncology
1.9$82.37+0.4%$3.07 billionN/A0.00Upcoming Earnings
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$25.56+0.0%$2.97 billion$306.49 million28.72Earnings Announcement
OPKO Health logo
OPK
OPKO Health
1.9$4.55+2.9%$2.96 billion$901.90 million-25.28Gap Down
VIE
Viela Bio
0.8$53.02+0.2%$2.91 billion$50 million-7.55Upcoming Earnings
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.